Your new post is loading...
Prof. G.V. Scagliotti and Prof. Tony Mok
CONTENTS:
-Introduction
-LUX-Lung 3: Improved Quality of Life, as Expected
-PSF v OS: why the disparity?
-Reversible and Irreversible TKI
-Crizotinib: Standard of Care for ALK-Positive Disease
-Unusual Toxicity Profile of Crizotinib
-Crizotinib of Benefit to ROS1-Positive Patients
-A Durg for Every Mutation
